Insmed Inc Stock Net Income
| INSM Stock | USD 25.02 0.08 0.32% |
Insmed Inc fundamentals help investors to digest information that contributes to Insmed's financial success or failures. It also enables traders to predict the movement of Insmed Stock. The fundamental analysis module provides a way to measure Insmed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Insmed stock.
As of the 1st of December 2023, Net Income is likely to drop to about (494.2 M). In addition to that, Net Income Common Stock is likely to drop to about (494.2 M). Insmed | Net Income |
Insmed Net Income Analysis
Insmed's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
More About Net Income | All Equity Analysis
Insmed Net Income |
|
Net Income | = | (Rev + Gain) | - | (Exp + Loss) |
Current Insmed Net Income | (481.53 M) |
Most of Insmed's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insmed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Insmed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Insmed is extremely important. It helps to project a fair market value of Insmed Stock properly, considering its historical fundamentals such as Net Income. Since Insmed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Insmed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Insmed's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Insmed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Insmed Inc reported net income of (481.53 Million). This is 241.1% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 184.33% higher than that of the company.
Insmed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insmed's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics of similar companies.Insmed is currently under evaluation in net income category among related companies.
Insmed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Insmed from analyzing Insmed's financial statements. These drivers represent accounts that assess Insmed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Insmed's important valuation drivers and their relationship over time.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 (projected) | ||
| Net Income Per Employee | (869.4K) | (584.7K) | (562.9K) | (709.1K) | (654.3K) | (705.9K) | |
| Average Assets | 690.9M | 726.0M | 799.7M | 1.1B | 1.2B | 1.3B | |
| Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (293.8M) | (205.9M) | (243.0M) | (369.2M) | (431.4M) | (442.8M) | |
| Earnings Before Interest Taxes and Depreciation Amortization USD | (293.8M) | (205.9M) | (243.0M) | (369.2M) | (431.4M) | (442.8M) | |
| Earnings before Tax | (324.1M) | (253.6M) | (292.7M) | (436.4M) | (480.2M) | (492.8M) | |
| Average Equity | 326.3M | 266.6M | 311.2M | 412.0M | 55.5M | 57.0M | |
| Enterprise Value | 755.7M | 2.0B | 3.2B | 3.0B | 3.1B | 2.5B | |
| Free Cash Flow | (271.1M) | (292.9M) | (225.6M) | (370.6M) | (410.3M) | (421.1M) | |
| Invested Capital | 287.6M | 513.0M | 500.2M | 793.9M | 1.5B | 1.6B | |
| Invested Capital Average | 320.5M | 448.3M | 513.2M | 711.5M | 1.2B | 1.3B | |
| Market Capitalization | 1.0B | 2.1B | 3.4B | 3.2B | 2.7B | 2.4B | |
| Tangible Asset Value | 545.9M | 688.6M | 746.9M | 1.0B | 1.5B | 1.6B | |
| Working Capital | 439.2M | 470.0M | 504.1M | 701.9M | 1.1B | 1.2B |
Insmed Institutional Holders
Institutional Holdings refers to the ownership stake in Insmed that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Insmed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Insmed's value.| Last Transaction | Type | Shares | Value | Absolute Investment Advisers Llc | 2023-09-30 | Debt | 8.7 M | 8.6 B | Vanguard Group Inc | 2023-09-30 | Common Shares | 14.3 M | 362.2 M | Price T Rowe Associates Inc | 2023-09-30 | Common Shares | 10.4 M | 262.8 M | Blackrock Inc | 2023-09-30 | Common Shares | 10.4 M | 262.4 M | T Rowe Price Investment Management Inc | 2023-09-30 | Common Shares | 8.3 M | 210.2 M | Deep Track Capital Lp | 2023-09-30 | Common Shares | 6 M | 151.5 M | Palo Alto Investors Lp | 2023-09-30 | Common Shares | 5.9 M | 148.7 M | State Street Corp | 2023-09-30 | Common Shares | 5.1 M | 127.6 M | Macquarie Group Ltd | 2023-09-30 | Common Shares | 4.7 M | 117.5 M | Fmr Llc | 2023-09-30 | Common Shares | 4.3 M | 108.7 M | Deerfield Management Company Lp Series C | 2023-09-30 | Debt | 108.9 M | 107.6 M |
Insmed Fundamentals
| Return On Equity | -14.53 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (2.58) % | ||||
| Operating Margin | (1.75) % | ||||
| Current Valuation | 3.97 B | ||||
| Shares Outstanding | 143.06 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 98.71 % | ||||
| Number Of Shares Shorted | 14.17 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 48.18 X | ||||
| Price To Sales | 10.89 X | ||||
| Revenue | 245.36 M | ||||
| Gross Profit | 190.23 M | ||||
| EBITDA | (458.21 M) | ||||
| Net Income | (481.53 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 1.18 B | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | (2.02) X | ||||
| Cash Flow From Operations | (400.44 M) | ||||
| Short Ratio | 10.72 X | ||||
| Earnings Per Share | (5.29) X | ||||
| Target Price | 41.42 | ||||
| Number Of Employees | 736 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 3.59 B | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (2.7 B) | ||||
| Working Capital | 1.08 B | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
| Z Score | -0.43 | ||||
| Annual Yield | 0.014 % | ||||
| Net Asset | 1.66 B |
About Insmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insmed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for 2023 | ||
| Net Income | -481.5 M | -494.2 M | |
| Net Income Common Stock | -481.5 M | -494.2 M | |
| Net Income Per Employee | -654.3 K | -705.9 K |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Insmed without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insmed Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Insmed Piotroski F Score and Insmed Altman Z Score analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Insmed Stock analysis
When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.29) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.167 | Return On Assets (0.36) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.